8/4/2020 4:03:07 PM
Curis Q2 Net Loss $6.7 Mln Or $0.17/Shr Vs Net Loss $7.2 Mln Or $0.22/Shr Last Year
7/7/2020 8:01:18 AM
Curis Says First Patient Dosed In Its Phase 1 Trial Evaluating CA-4948
6/11/2020 9:28:33 AM
Curis Plans $17.5 Mln Registered Direct Offering
6/10/2020 8:02:15 AM
Curis Says FDA Cleared Its IND Application For CI-8993
5/12/2020 4:03:23 PM
Curis Q1 Loss/share $0.28 Vs. Loss $0.30 Year Ago
3/19/2020 4:05:35 PM
Curis Q4 Loss/share $0.26 Vs. Loss $0.18 Year Ago
2/27/2020 8:03:12 AM
Curis Announces $30 Mln Common Stock Purchase Agreement With Aspire Capital Fund
1/13/2020 8:05:08 AM
Curis, DarwinHealth Collaborate To Characterize Biomarkers And Tumor Subtype Alignments For Fimepinostat In DLBCL
1/7/2020 8:06:40 AM
Curis Enters Option, License Agreement To Acquire Exclusive, Worldwide Rights From ImmuNext For Anti-VISTA Antibodies
12/6/2019 7:32:42 AM
Curis Announces Updated Preliminary Data From Phase 1 Dose Escalation Study Of CA-4948
12/6/2019 7:02:22 AM
Curis Announces Positive Safety, Tolerability And Pharmacokinetic Data In Phase 1 Study Of Fimepinostat With Venetoclax